

Strong revenue performance and growth into 2024

Sobi Q4 and FY 2023 results

Conference call for investors and analysts

08 February 2024



This presentation contains certain forward-looking statements with respect to certain of the Company's current expectations and projections about future events. These statements, which sometimes use words such as "intend," "proposed," "plan," "expect," and words of similar meaning, reflect management's beliefs and expectations and involve a number of risks, uncertainties and assumptions that could cause actual results and performance to differ materially from any expected future results or performance expressed or implied by the forward-looking statement. Statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The information contained in this presentation is subject to change without notice and, except as required by applicable law, the Company does not assume any responsibility or obligation to update publicly or review any of the forward-looking statements contained in it. You should not place undue reliance on forward-looking statements, which speak only as at the date of this presentation.

Agenda





Summary and Q&A

Double-digit performance

Revenue

- Q4 SEK 6,844 M, +14% (+15% at CER)
- FY SEK 22,123 M, +18% (+12% at CER); exceeding our growth outlook

EBITA margin adjusted 38% in Q4 and 34% in FY; outlook fully met

Strategic portfolio¹ drives growth

- Accounting for 40% of sales in Q4
- Strong growth of Doptelet[®] outside of China (+59% for Q4, 62% for FY at CER)
- Vonjo[®] sales SEK 706 M FY

Key milestones for late-stage pipeline

Aspaveli /Empaveli: Positive phase 2 data in C3G & IC-MPGN; Phase 3 study fully enrolled Gamifant: Completed enrolment of EMERALD (1st cohort in MAS/Still's)

2024 guidance

Revenue: anticipated to grow by a high single-digit percentage at CER **Margins adjusted:** anticipated to be in the mid-30s percentage of revenue

• Beyfortus[™] royalties SEK 1,153 M FY

Strategic portfolio delivering on growth aspirations

- Gamifant[®] continues strongly (+107% for Q4, 77% for FY at CER)
- Elocta[®] and Alprolix[®] stable (+6% FY at CER)

Kineret: Approved for FMF and CAPS in China

Lead in Haematology



Captur	e the	value
of the	pipeli	ne

Sobi strategy



Grow Immunology and Specialty Care







Business growth at CER of 15% in Q4




Growth driven by launch medicines and geographical expansion

Revenue by segmen	t					Revenue by region					
	Q4 2023	change	FY 2023	change	contrib.		Q4 2023	change	FY 2023	change	contrib.
	SEK M	%	SEK M	%	%		SEK M	%	SEK M	%	%
Haematology	3,640	+21	13,370	+17	60	Europe	2,232	+14	8,511	+6	38
naematology	3,040	121	13,370	'1/	00	North America	2,687	-6	8,241	+6	37
– Haemophilia	2,297	+10	8,608	+6	39	Royalties Beyfortus and	977	NA	1,298	NA	6
Immunology	2,905	+10	7,635	+9	35	efanesoctocog alfa					
					5	International	620	-22	2,653	+7	12
Specialty Care	298	-9	1,119	-17		International (ex Doptelet China base effect)	620	+21	2,076	+54	
						Other	329	-2	1,421	-5	6
Total	6,844	+15	22,123	+12	100	Total	6,844	+15	22,123	+12	100

Revenue at actual exchange rates; change at constant exchange rates (by segment and geographic area). International region previously called rest of the world. Other refers to royalty not including Beyfortus and efanesoctocog alfa that are not attributable to a specific region according to the split above

Strategic portfolio set to be the main contributor to our revenue




 In Q4 the strategic portfolio already contributed 40% of total business

- Royalties of Beyfortus and efanesoctocog alfa will become catalyst for transformation
- Strong fundamentals for future growth:
 - Strategic Portfolio
 - International diversification
 - Near-term Pipeline

Lega cy a ctivities: Synagis, manufacturing and Doptelet China. Foundational portfolio: Elocta, Alprolix, Kineret, Orfadin, Tegsedi, Waylivra, & other. La unch medicines: As peveli/Empaveli, Doptelet, Gamifant, Vonjo and Zynlonta


Growth continues through pipeline and geographical ⁽⁾SODI expansion



Share of yet to achieve potential for illustration purposes

Haematology: Doptelet ex China showing strong momentum (growth of 59% at CER in Q4)






- US: Increased uptake driven by higher market share and duration of treatment
- Europe and international ongoing growth driven by launches
- Sales growth 62% at CER (ex-China) for FY 2023
 - Q4 SEK 555 M, FY SEK 2,125 M



Haematology: Aspaveli/Empaveli launch progressing



Phase 3 data (VALIANT study) in Nephrology expected in 2024



PNH

- Launched in more than 27 countries across EU, International region and Canada
- CHMP positive opinion for 1L PNH received on January 25^{th}
- Q4 sales SEK 186 M, FY SEK 594 M


Nephrology

- Phase 2 NOBLE study in patients with recurrent C3G or primary IC-MPGN shows positive results at 12 weeks
- Pegcetacoplan is clearing deposits that cause kidney damage and may block future damage from occurring
- VALIANT phase 3 data expected in 2024, enrolment completed in Q4 2023



Haematology: Vonjo launch elements in place for growth in 2024

The evolution of new patient starts during the CTI transition period has impacted Q4 results and will have some effect in Q1




Vonjo launch progressing with new sales force

- Q4 sales SEK 322 M, FY SEK 706 M significantly contributing to the business
- Q4 saw the highest number of new patients starting treatment since launch.
- Organization is in place under one leadership
- Market research confirmed a strong preference share of Vonjo in a large group of myelofibrosis patients with low platelet count
- In addition to being the preferred option in its indicated population of intermediate and highrisk MF patients with a platelet count <50K, the updated NCCN guidelines recommend the use of pacritinib as a potential treatment option in patients with myelofibrosis associated anemia



Haematology: Stable haemophilia franchise growth with revenues +6% for FY 2023



Elocta

- Patient growth
- Geographical expansion
- Favourable phasing


Alprolix

• Patient growth compensating for pricing pressure





Immunology: Beyfortus demand overcompensated for (Sob) Synagis decline




Synagis

- Sales impacted by later RSV season and launch of Beyfortus
- FY SEK 2,422 M

Beyfortus royalties

- Strong launch in US with very high demand
- Royalties in Q4 SEK 890 M and for the full year SEK 1,153 M



Immunology: Gamifant strategy increasing market share SODI Kineret: increased demand in Europe and US



Gamifant


- Growth driven by:
 - Increased number of patients from new and established centers
 - Higher average patient weight/dosing mix

Kineret

- Growth from Europe and US
- Full year impacted by strong Q1 2022 Covid-19 sales









Agenda





Q4 2023 Revenue and profit & loss





Absolute a mounts in SEK million (except EPS) and at actual exchange rates; change at actual exchange rates (statutory view).

Amounts in SEK M	Q4 2023	Q4 2022	Change	Full-year 2023
Total revenue	6,844	5,991	14%	22,123
Gross profit adjusted ^{1,2}	5,478	4,683	17%	17,162
Gross margin adjusted ^{1,2}	80%	78%		78%
EBITA ^{1,2}	2,502	2,455	2%	7,075
EBITA adjusted ^{1,2}	2,583	2,455	5%	7,494
EBITA margin ^{1,2}	37%	41%		32%
EBITA margin adjusted ^{1,2}	38%	41%		34%
Profit for the period	1,026	1,386	-26%	2,409
Earnings per share, before dilution, SEK ^{1,2,3}	3.02	4.47	-32%	7.47
Earnings per share, before dilution, SEK adjusted ^{1,2,3}	3.21	4.47	-28%	8.55
Operating cash flow	1,073	1,893	-43%	4,470
Net debt	19,265	7,406		19,265

1. Alternative performance measures (APM), see the Q4 and FY 2023 report for further information

2. Items a ffecting comparability (IAC), see the Q4 and FY 2023 report for further information

3. Comparatives have been adjusted to consider the bonus issue element in the rights issue, for which the final outcome was announced on 19 September 2023



Revenue

Anticipated to grow by a high single-digit percentage at CER¹

EBITA margin adjusted²

Anticipated to be in the mid-30s percentage of revenue




Agenda





Pipeline and medical highlights



1.Subsequent event in January 2024

C3G:Complement 3 Glomerulopathy. IC-MPGN: Immune-complex-mediated glomerulonephritis. PNH: Paroxysmal nocturnal haemoglobinuria. CAD: Cold agglutinin disease. FMF: Familial mediterranean fever. CAPS: Cryopyrin associated periodic syndromes.

Significant events ahead in 2024

Anticipated major upcoming pipeline news flow


Efanesoctocog alfa EU decision	SEL-212 & Gamifant US submissions		Doptelet & Kineret GeoExpansion CN, JP		
2024 H1		2	2024 H2		
Doptelet – ITP:Regulatory decision in China	\bigcirc		i – C3G & IC-MPGN:		
Efanesoctocog alfa – Haemophilia A:Regulatory decision in EU	\bigcirc	Doptelet – ITP:Regulatory subm	hission in Japan		
Kineret – Still's disease:Regulatory decision in China	H	Gamifant – sHLH / rheumatological dis • Regulatory subm	seases:		
 SEL-212 – Chronic Refractory Gout: Regulatory submission in the US 	H	(Still's disease cohort)			

ITP: immune thrombocytopenia. C3G and IC-MPGN: Complement 3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis. s HLH / MAS: secondary hemophagocytic lymphohistic cytosis / macrophage a ctivation s yndrome in patients with underlying rheumatological diseases, s pecifically Still's disease and systemic lupus erythematosus



Agenda





Summary: Growth and pipeline progress



Significant growth	Revenue Q4: SEK 6,844 M, +14%, +15% at CER Revenue FY: SEK 22,123 M, +18%, +12% CER	Second consecutive year as me mber of DJSI Europe
Steady base and expanded position	Elocta and Alprolix 6% CER growth at FY Growing contribution in Q4 from launch medicines: Doptelet SEK 727 M, Gamifant SEK 497 M, Vonjo SEK 322 M	Sustainability Indices Powered by the S&P Global CSA Selected as a member of the S&P Yearbook
Key pipeline milestones for Q4	Beyfortus royalties SEK 890 M in Q4, SEK 1,153 M for FY Pegcetacoplan: positive phase 2 results in C3G and IC-MPGN presented at ASN 2023; VALIANT ph3 fully enrolled Gamifant: enrolment complete in the first cohort in MAS / Still's disease in the EMERALD study Kineret — approval in China for FMF and CAPS	ABC Company ABC Industry Bustainability Yearbook Member S&P Global Corporate Sustainability Assessment (CSA) Score 2023 BMP Ched CAS how SDC NOT Company Compa
2024 Guidance	Revenue to be high single-digit percentage at CER Adj EBITA to be in the mid-30s percentage of revenue	S&P Global Sustainable'



Appendix: Q4 2023 sustainability performance



Highlights in Q4 2023



- Milestones toward increased access ٠
 - Kineret (anakinra) received first approval in China as treatment for FMF.
 - Health Canada approval for Doptelet (avatrombopag) for two indications in thrombocytopenia.
- Raising awareness and supporting patients
 - Shared knowledge on PNH during events in Japan, Dubai and the UK.
 - Presented new data connected to six diseases at the 65th annual ASH* meeting in San Diego, USA.



Access to treatment


17 PATTERESSIPPE FOR THE GOALS

- Patient centricity and engagement
- Patient and product safety
- Ethical marketing and sales
- Transparent and ethical R&D



Commitment to the UN Global Compact. Contribution to the 2030 Agenda,

the UN Sustainable Development Goals and the Paris Agreement



- Reduction of environmental footprint
- Responsible sourcing
- Compliance and corruption prevention

Highlights in Q4 2023



- Caring for employees ٠
 - Continued roll-out of Diversity, Equity and Inclusion (DEI) programme; launch of DEI toolbox and learning events.
 - Annual global employee index at 73, an increase of 4 points.
- Compliance and anti-corruption •
 - Annual compliance and ethics week
 - Launch of new global training programme on anti-corruption and anti-bribery.

Member of **Dow Jones** Sustainability Indices

Powered by the S&P Global CSA

Second consecutive year as member of DJSI Europe Selected as a member of the S&P Yearbook



🍛 Sustainable1

S&P Globy

Current development pipeline



Major ongoing clinical studies and medicines in registration in a major region or country

Phase 2	Phase 3		Registration	
Aspaveli/Empaveli (pegcetacoplan)	Aspaveli/Empaveli (pegcetacoplan)	G,	efanesoctocog alfa	C,
Transplant-associated thrombotic microangiopathy after allogenic haematopoietic stem cell transplantation	C3 glomerulopathy and immune-comple membranoproliferative glomerulonephrit		Haemophilia A	
	Doptelet		Doptelet (avatrombopag)	Q
	Immune thrombocytopenia (in Japan and paediatric indication)	ł	Immune thrombocytopenia (in Chir	na)
			Kineret (anakinra)	Q
	Zynlonta (loncastuximab tesirine)	R,	In China: Still's disease	
	Diffuse large B-cell lymphoma (second lir	ne)		
	VONJO (pacritinib)	G,		
	Myelofibrosis with severe thrombocytope (Confirmatory trial)	nia		
Haematology Immunology	Gamifant (emapalumab)			
Haematology Immunology	sHLH / MAS in rheumatological diseases			
	SEL-212	C.		
	Chronic refractory gout			

ITP: immune thrombocytopenia.

C3G and IC-MPGN: C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis.

s HLH / MAS: secondary hemophago cytic lymphohistic cytosis / macrophage a ctivation syndrome in patients with underlying rheumatological diseases, specifically Still's disease and systemic lupus erythematosus.

CAPS: cryopyrin-associated periodic syndromes.

CRG: chronic refractory gout.

Upcoming milestones

2024 H1

Doptelet-ITP:

• Regulatory decision in China

Efanesoctocog alfa – Haemophilia A:

• Regulatory decision in EU

Kineret – Still's disease:

• Regulatory decision in China

SEL-212 – Chronic Refractory Gout:

• Regulatory submission in the US

2024 H2

Aspaveli/Empaveli – C3G & IC-MPGN:

• VALIANT phase 3 study data readout

Doptelet-ITP:

• Regulatory submission in Japan

Gamifant – sHLH / MAS in rheumatological diseases:

 Regulatory submission in the US (Still's disease cohort)

Thank you

Sobi is a trademark of Swedish Orphan Biovitrum AB (publ). © 2022 Swedish Orphan Biovitrum AB (publ) – All rights reserved Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm • Sweden www.sobi.com